科学家鉴别出治疗三阴性乳腺癌的潜在靶点

  近日，来自堪萨斯大学医学院的研究者通过研究鉴别出了一种治疗乳腺癌的潜在靶点。三阴性乳腺癌是由于患者机体缺失雌激素受体、孕酮受体及Her2受体这三个受体而得名，该疾病在所有类型乳腺癌中占12%至17%，由于三种受体的缺失使得激素疗法如他莫昔芬疗法不可能去治疗三阴性乳腺癌，而三阴性乳腺癌也更易于恶化，而且相比其它乳腺癌更易复发。
当前由于缺少治疗三阴性乳腺癌的疗法，因此文章中研究人员检测了一系列激酶家族蛋白，而近些年来研究人员在转移的三阴性乳腺肿瘤及侵袭组织中发现了非典型的蛋白激酶C信号通路。研究者Soumen Paul表示，文章中我们研究了三阴性乳腺癌侵袭过程中非典型蛋白激酶C lambda/iota；在其它实验中我们分析了扩散到肝脏、肺脏及其它器官中的乳腺癌组织样本，结果发现非典型蛋白激酶C lambda/iota可以影响细胞的生长，而且在转移性的乳腺癌中处于高度表达和磷酸化状态。
  为了进一步深入研究，研究人员提出了三阴性乳腺癌组织中的一种特殊蛋白，通过对小鼠进行研究发现剔除该蛋白可以明显减缓乳腺肿瘤组织的生长。Paul博士表示，我们发现这种蛋白在转移性的三阴性乳腺癌中处于高度表达的状态，而且当从三阴性乳腺癌剔除该蛋白时癌细胞就变得不再具有侵袭性了，而且肿瘤的生长也减缓了，这就提示我们可以开发一种靶向疗法来治疗三阴性乳腺癌。
  目前研究人员正同化学家们进行联合研究来设计可以抑制非典型蛋白激酶C lambda/iota的类似物，从而通过靶向作用特殊蛋白来抑制乳腺癌的转移和复发。（转化医学网360zhyx.com）
  本文系转化医学网原创翻译整理，欢迎转载！转载请注明来源并附原文链接。谢谢！
转化医学网推荐的新闻阅读：

A team at the University of Kansas School of Medicine has identified a potential target for treating breast cancer, including a particularly deadly form of the disease.
So-called "triple-negative" breast cancer represents between 12 and 17 percent of all breast cancers. It derives its name from the lack of receptors for estrogen, progesterone and Her2. The absence of these receptors rules out proven hormone therapies such as tamoxifen. Triple-negative breast cancer can be more aggressive and is more likely to recur than other breast cancers.
Because of the lack of existing therapies, the KU team chose to examine a member of a family of protein kinase enzymes. In recent years, atypical protein kinase C signaling has been found in the tissue invasion and metastasis of multiple tumors.
The research team, including Soumen Paul, Ph.D., associate professor, Arindam Paul, Ph.D., assistant professor, and Ossama Tawfik, professor, M.D., Ph. D., all in the Department of Pathology and Laboratory Medicine, and their colleagues, studied atypical protein kinase c lambda/iota signaling during the invasive progression of triple-negative breast cancer. Among other tests, they looked at tissue samples of breast cancer that had spread to the liver, lung and other organs. They found that atypical protein kinase c lambda/iota, which is known to influence cell growth, was highly expressed and phosphorylated in metastatic breast cancers......